The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. - Wikidata - awgldk - TriplyDB

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

http://www.wikidata.org/entity/Q39851104

about

Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Update of literature from cystic fibrosis registries 2012-2015. Part 6: Epidemiology, nutrition and complications.Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis The Dynamics of Disease Progression in Cystic Fibrosis.Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States.Early Lung Function Decline in Cystic Fibrosis: Can Registry Data Explain Divergent Phenotypes?Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor Risk factors for mortality before age 18 years in cystic fibrosis.Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood.Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study.Data that empower: The success and promise of CF patient registries.Air pollution exposure is associated with MRSA acquisition in young U.S. children with cystic fibrosis.Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV1 < 30% of Predicted in the United States.Reducing practice variation through clinical pathways-Is it enough?Flexible semiparametric joint modeling: an application to estimate individual lung function decline and risk of pulmonary exacerbations in cystic fibrosis.Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results.Clinical Characteristics of Cystic Fibrosis Patients Prior to Lung Transplantation: An International Comparison between Canada and the United States.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States.Comparative Effectiveness Research in Pediatric Respiratory Disease: Promise and Pitfalls.Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.Pregnancy among cystic fibrosis women in the era of CFTR modulators.The U.S. Food and Drug Administration's Experience with Ivacaftor in Cystic Fibrosis. Establishing Efficacy Using In Vitro Data in Lieu of a Clinical Trial.The effect of the affordable care act dependent coverage provision on patients with cystic fibrosis.Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.Generalized accelerated recurrence time model for multivariate recurrent event data with missing event type.Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer.Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.Cystic Fibrosis: The Dawn of a New Therapeutic Era.Dissection of the Role of VIMP in Endoplasmic Reticulum-Associated Degradation of CFTRΔF508.Big data: Some statistical issues.Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.Microbial Interactions in the Cystic Fibrosis Airway Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients

P2860

Q30238814-C70F7389-ED65-4619-A35C-56E8E4FA9293 Q30245013-83222FBE-7FAE-4BB3-A35C-D80B64071705 Q33757918-F771F5DC-8BE8-4FCE-B630-C36006BBD3EE Q33785116-78987459-46CC-4614-882B-C8FC7CED55E8 Q36036190-E79AC3FF-3C0D-4206-80D7-98B100132762 Q36254493-A5562389-6744-4CF4-B790-9FE33724F036 Q36371926-84B41D6F-DCDC-4BE7-B75B-270DD9E09CD3 Q37602780-04A3B79B-EE4F-4C57-89B7-CCDB6ACE245D Q38823471-009347AA-CBF1-4ED0-8EB8-1F039DBD493E Q38836539-D047C028-4E7C-4341-9904-50E9A1175AA6 Q38886356-B946B463-F2C2-48A0-8391-5616EA95DB67 Q40041155-CB5A58D1-47C9-4BC5-8717-F9039D97BCC8 Q40105439-61FE4821-63DF-47D6-9B2E-70ADFDEEAE0A Q40361294-FA315B93-D3F8-40F9-B8A3-E8512A10173F Q45051726-9F2A87A2-881D-4204-B564-42F33AD34B2D Q45942214-D322F20F-9D5E-4517-8DD6-62465958D1BA Q46084537-F2FC0DC8-1BED-4E05-BB4B-64795983FDED Q46811475-6386086B-ED7F-4040-9011-1CC8568CBD4E Q47225533-692FA44C-0277-43E3-B794-C8D9B1E7789E Q47656318-E02DAFC9-644B-4071-AAAB-436E9AA2AA70 Q47663557-C4E27523-E778-4E34-AA47-01DB7ACD0CEB Q47701149-14E43AD3-3299-449A-900E-788A30E02CFD Q47720458-099D48C7-E72B-490E-8841-C2CF300BBE4D Q47764517-E004F7C5-DC9C-4C78-A7E8-D7F40801F2EB Q47819849-3997F835-24E9-434C-92A2-585E1F2CC405 Q47983937-329F5F59-15BE-49FC-9B70-F8EA471EE924 Q48021227-95638BD6-C458-4741-838B-9B4A5FA66A41 Q48503125-03A99031-57DA-4683-A959-10307EA37978 Q48611600-FD6D374A-A8E9-4019-8C3F-E37D20E64BD5 Q50106250-39F52B52-C403-4F23-B21F-F873A4011699 Q51424428-92A919D0-0AB8-4227-B0AD-57DD9768D9C9 Q52349764-F73B57D7-577B-49C1-A92D-6FEDB5D4E2DA Q55286292-0CA9703D-6D9F-4D85-AB30-B2731AC51DCE Q55517629-1DF05EAD-8A6F-4B2F-A588-475BFC220D5F Q57174565-2E57005A-C89F-4361-8C5A-8F3CCE308A4B Q58700574-14B6E7E2-3595-4481-ACF9-E9D121176F13

P2860

The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry.

http://www.wikidata.org/entity/Q39851104

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@en

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@nl

type

label

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@en

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@nl

prefLabel

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@en

The Cystic Fibrosis Foundation ...... bservational Disease Registry.

@nl

P1433

Q39851104-807E3662-D861-43B4-BF9E-CC58B6537436

P1476

Q39851104-0394AAA0-B6C5-4FDF-8DF9-9642E7631DF3

P2093

Q39851104-027C5AAD-AD23-471B-B791-0BF5586DB674

Q39851104-0E717FBE-8DB4-4E48-8ECB-7A89271DC1A9

Q39851104-1DECC8AD-3B10-4CBF-A5E1-8CA6331E4E67

Q39851104-3B0A5075-F81E-4F1B-AEC3-E52409DCBB5D

Q39851104-9EF67120-875E-49D3-B960-6EE88CD31898

Q39851104-AEA94AC9-B7FD-47D8-AB02-E4F32AC38C17

Q39851104-E7BD48C9-1855-4E51-8510-49CE3C668ED1

P2860

Q39851104-09472C8B-7006-4D3F-8406-67F6BD9F69B7

Q39851104-0FE1CB9B-B436-47CD-9EF6-05B0681C8BA1

Q39851104-29E546D4-79A0-4541-9460-9ED1B08334C0

Q39851104-2F415B9E-AC2C-4BB6-BFC9-041D4AFC4E84

Q39851104-3418CAE6-D70D-4626-B57D-C6A6E3FAC5C9

Q39851104-3CD4CA32-A297-4BAB-834E-8AFD1603FD9A

Q39851104-4FDB9AD4-CF54-4F76-9CCB-69D53C84EC15

Q39851104-5009D1D8-77BF-4783-B12E-97A4527C0528

Q39851104-5A1ED891-5AE1-4C94-ABB0-159511F4156B

Q39851104-766EA54B-3E1C-471B-9137-2389E7A1DA0F

P304

Q39851104-3E2B498D-671E-4982-BBA3-5D3BB703D843

P31

Q39851104-B14360D0-E14E-4F8B-A064-EF36C48B84B2

P356

Q39851104-08FBE79D-4B79-45AF-864F-46F80708E30E

P433

Q39851104-81ED22A2-C182-4B4F-AB22-B796D1C29294

P478

Q39851104-3314C795-43AD-4DD3-9ED1-1A2CE554E7F3

P50

Q39851104-26FBE385-2221-49EB-9BBD-0A646B074EED

Q39851104-69D9DBF5-397D-4159-B3D6-96D3F9E7B9BF

P577

Q39851104-C51ECB10-D5D4-4CDB-A9DF-2104B6F550E2

P698

Q39851104-C13DAA68-7F83-418B-9604-698E810AE6DA

P921

Q39851104-152E5AC2-263B-4B3D-AB80-D7DD2DAEEA81

P356

ANNALSATS.201511-781OC

P1433

Proceedings of the American Thoracic Society

P1476

The Cystic Fibrosis Foundation ...... Observational Disease Registry

@en

P2093

Alexander Elbert

http://www.w3.org/2001/XMLSchema#string

Aliza K Fink

http://www.w3.org/2001/XMLSchema#string

Ase Sewall

http://www.w3.org/2001/XMLSchema#string

Bruce C Marshall

http://www.w3.org/2001/XMLSchema#string

Christopher Dowd

http://www.w3.org/2001/XMLSchema#string

Josh Ostrenga

http://www.w3.org/2001/XMLSchema#string

Kristofer M Petren

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

Use of 13 disease registries in 5 countries demonstrates the potential to use outcome data to improve health care's value.

Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

A checklist for retrospective database studies--report of the ISPOR Task Force on Retrospective Databases.

Newborn screening fact sheets.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Children and young adults with CF in the USA have better lung function compared with the UK.

Lung transplantation and survival in children with cystic fibrosis

A standardized approach to estimating survival statistics for population-based cystic fibrosis registry cohorts

The Cystic Fibrosis Foundation Patient Registry as a tool for use in quality improvement.

P304

1173-1179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1513/ANNALSATS.201511-781OC

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Christopher H Goss

P577

2016-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27078236

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis